{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:29:54Z","timestamp":1771882194228,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The standard to ensure utmost cancer treatment is a prerequisite in national cancer plans for comprehensive cancer centers (CCCs) and ensured through multidisciplinary tumor boards (MTBs). Despite these being compulsory for CCCs, various analyses on MTBs have been performed, since MTBs are resource-intensive. Outcome measures in these prior analyses had been survival (OS), MTB-adherence and -satisfaction, inclusion of patients into clinical trials and better cancer care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>A publication from Freytag et al. performed an analysis in multiple tumor entities and assessed the effect of number of MTBs. By matched-pair analysis, they compared response and OS of patients, whose cases were discussed in MTBs vs. those that were not. The analysis included 454 patients and 66 different tumor types. Only patients with <jats:underline>&gt;<\/jats:underline>\u20093 MTBs showed a significantly better OS than patients with no MTB meeting. Response to treatment, relapse free survival and time to progression were not found to be better, nor was there any difference for a specific tumor entity with vs. without MTB discussions.<\/jats:p>\n                <jats:p>An in-depth discussion of these results, with respect to the literature (PubMed search: \u201cMTBs AND cancer\u201d) and within the author group, including statisticians specialized in data analysis of cancer patients and questions addressed in MTBs, was performed to interpret these findings. We conclude that the results by Freytag et al. are deceiving due to an \u201cimmortal time bias\u201d that requires more careful data interpretation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The result of Freytag et al. of a seemingly positive impact of higher number of MTBs needs to be interpreted cautiously: their presumed better OS in patients with <jats:underline>&gt;<\/jats:underline>\u20093 MTB discussions is misleading, due to an immortal time bias. Here patients need to survive long enough to be discussed more often. Therefore, these results should not lead to the conclusion that more MTBs will \u201cautomatically\u201d increase cancer patients\u2019 OS, rather than that the insightful discussion, at best in MTBs and with statisticians, will generate meaningful advice, that is important for cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-07878-6","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:05:22Z","timestamp":1613779522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gengenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Farthmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Herget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"7878_CR1","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1055\/s-0043-100054","volume":"142","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Selder R, Pandurevic M, M\u00f6ller M, Ihorst G, Waldschmidt J, et al. Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable comprehensive cancer center instrument. Dtsch Med Wochenschr 1946. 2017;142:e51\u201360. https:\/\/doi.org\/10.1055\/s-0043-100054.","journal-title":"Dtsch Med Wochenschr 1946"},{"key":"7878_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.critrevonc.2010.06.005","volume":"79","author":"P Barth\u00e9l\u00e9my","year":"2011","unstructured":"Barth\u00e9l\u00e9my P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V, et al. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol. 2011;79:196\u2013204. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.06.005.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7878_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2718","volume":"344","author":"EM Kesson","year":"2012","unstructured":"Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344:e2718. https:\/\/doi.org\/10.1136\/bmj.e2718.","journal-title":"BMJ."},{"key":"7878_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27384","volume":"65","author":"J Kreyer","year":"2018","unstructured":"Kreyer J, Ranft A, Timmermann B, Juergens H, Jung S, Wiebe K, et al. Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. Pediatr Blood Cancer. 2018;65:e27384. https:\/\/doi.org\/10.1002\/pbc.27384.","journal-title":"Pediatr Blood Cancer"},{"key":"7878_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1188\/18.CJON.656-662","volume":"22","author":"J Peckham","year":"2018","unstructured":"Peckham J, Mott-Coles S. Interprofessional Lung Cancer Tumor Board: the role of the oncology nurse navigator in improving adherence to national guidelines and streamlining patient care. Clin J Oncol Nurs. 2018;22:656\u201362. https:\/\/doi.org\/10.1188\/18.CJON.656-662.","journal-title":"Clin J Oncol Nurs"},{"key":"7878_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/10428194.2019.1695051","volume":"61","author":"G Graziani","year":"2020","unstructured":"Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, et al. Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective \u201cDeutsche Studiengruppe MM\u201d (DSMM) and \u201cEuropean Myeloma Network\u201d (EMN) analysis. Leuk Lymphoma. 2020;61:875\u201386. https:\/\/doi.org\/10.1080\/10428194.2019.1695051.","journal-title":"Leuk Lymphoma."},{"key":"7878_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12885-020-06809-1","volume":"20","author":"M Freytag","year":"2020","unstructured":"Freytag M, Herrlinger U, Hauser S, Bauernfeind FG, Gonzalez-Carmona MA, Landsberg J, et al. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer. 2020;20:355. https:\/\/doi.org\/10.1186\/s12885-020-06809-1.","journal-title":"BMC Cancer"},{"key":"7878_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3324\/haematol.2018.188516","volume":"103","author":"M Engelhardt","year":"2018","unstructured":"Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, et al. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica. 2018;103:755\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.188516.","journal-title":"Haematologica."},{"key":"7878_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00277-015-2426-8","volume":"94","author":"G Ihorst","year":"2015","unstructured":"Ihorst G, Waldschmidt J, Schumacher M, W\u00e4sch R, Engelhardt M. Analysis of survival by tumor response: have we learnt any better? Ann Hematol. 2015;94:1615\u20136. https:\/\/doi.org\/10.1007\/s00277-015-2426-8.","journal-title":"Ann Hematol"},{"key":"7878_CR10","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1080\/10428194.2018.1448084","volume":"59","author":"L Gengenbach","year":"2018","unstructured":"Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, K\u00f6hler M, et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leuk Lymphoma. 2018;59:2692\u20139. https:\/\/doi.org\/10.1080\/10428194.2018.1448084.","journal-title":"Leuk Lymphoma"},{"key":"7878_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232\u201342. https:\/\/doi.org\/10.3324\/haematol.2013.099358.","journal-title":"Haematologica."},{"key":"7878_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","volume":"103","author":"F Gay","year":"2018","unstructured":"Gay F, Engelhardt M, Terpos E, W\u00e4sch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103:197\u2013211. https:\/\/doi.org\/10.3324\/haematol.2017.174573.","journal-title":"Haematologica."},{"key":"7878_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol Off J Am Soc Clin Oncol. 1983;1:710\u20139. https:\/\/doi.org\/10.1200\/JCO.1983.1.11.710.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7878_CR14","doi-asserted-by":"publisher","unstructured":"Dold SM, M\u00f6ller M-D, Ihorst G, Langer C, P\u00f6nisch W, M\u00fcgge L-O, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2020.254235.","DOI":"10.3324\/haematol.2020.254235"},{"key":"7878_CR15","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","volume":"105","author":"M Engelhardt","year":"2020","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Sp\u00e4t-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105:1183\u20138. https:\/\/doi.org\/10.3324\/haematol.2019.242958.","journal-title":"Haematologica."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07878-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07878-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07878-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:06:29Z","timestamp":1613779589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07878-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7878"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07878-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}